FDA Approves Tauklarify: What the New Tau PET Imaging Agent Means for Alzheimer’s Assessment
The U.S. Food and Drug Administration (FDA) has approved Tauklarify, also known as florquinitau F 18 injection or MK-6240, a new radiodiagnostic agent designed to support brain imaging in adults undergoing evaluation for Alzheimer’s disease. The approval represents another development in the growing use of advanced imaging techniques to identify biological features associated with the disease.
Tauklarify is an F18-labeled tau positron emission tomography, or PET, imaging agent. It is intended to help identify tau neurofibrillary tangle pathology in the brains of adults with cognitive impairment who are being evaluated for Alzheimer’s disease. The approval was announced by Lantheus Holdings on August 14, 2026.
What Is Tauklarify?
Tauklarify is a radiopharmaceutical used during PET imaging of the brain. Its purpose is not to treat Alzheimer’s disease. Instead, it is a diagnostic imaging tool that can provide information about the presence of tau neurofibrillary tangle pathology.
Tau is a protein associated with the development and progression of Alzheimer’s disease. Abnormal accumulation of tau can form structures known as neurofibrillary tangles. Advanced imaging technologies that can visualize disease-related proteins may give clinicians additional information when evaluating patients with cognitive impairment.
According to the source material, Tauklarify is intended for adults with cognitive impairment who are being evaluated for Alzheimer’s disease. Its use is specifically focused on identifying tau neurofibrillary tangle pathology.
The company has also stated that tau PET imaging can complement other diagnostic approaches, including amyloid PET and clinical evaluation. This means Tauklarify is part of a broader diagnostic process rather than a standalone replacement for other assessments.
How Was the Approval Supported?
The approval was supported by two blinded image interpretation studies. Together, the studies evaluated Tauklarify PET images from more than 500 participants who had taken part in three clinical trials.
The participants represented a range of cognitive conditions. The clinical trial population included people with mild cognitive impairment, individuals with mild Alzheimer’s disease dementia, and cognitively unimpaired participants.
Each participant received an approximate intravenous dose of 185 MBq, equivalent to 5 mCi, of Tauklarify for tau PET imaging.
During the studies, independent readers who had been trained in interpreting the images reviewed the scans. The readers were blinded to clinical information and amyloid beta PET results. The scans were categorized as positive or negative for tau neurofibrillary tangle pathology and were assessed against a predetermined reference standard.
In Study 1, 279 subjects were evaluated. Positive Percent Agreement among readers ranged from 80% to 88%, while Negative Percent Agreement ranged from 98% to 99%. The study also reported a high level of agreement between readers.
Study 2 included 338 subjects. Positive Percent Agreement ranged from 68% to 82%, and Negative Percent Agreement ranged from 93% to 99%. Inter-reader agreement was again reported to be high.
These findings provided evidence supporting the ability of trained readers to interpret Tauklarify PET images in the studied populations.
Why Tau Imaging Matters in Alzheimer’s Disease
Alzheimer’s disease is a progressive neurological disorder associated with declining cognitive and functional abilities. As the number of people living with the disease continues to grow, tools that can provide more information about its underlying biology are increasingly important.
Tau and amyloid are two key biological features associated with Alzheimer’s disease. Imaging technologies that can identify these features may help clinicians better understand the pathology present in a patient's brain.
Tau PET imaging may therefore provide information that complements clinical assessments and other biomarker-based approaches. The availability of an FDA-approved tau imaging agent could also support research into Alzheimer’s disease and the development of potential treatments.
However, imaging results should be interpreted within the appropriate clinical context. A PET scan is one component of a larger evaluation, and the information it provides does not necessarily establish the complete clinical picture.
Safety Information
Safety was evaluated in 1,734 subjects in the Tauklarify development program.
The most frequently reported adverse reactions, each occurring in at least 0.1% of participants, included headache, nausea, injection site reactions, dizziness, and abdominal discomfort.
The source also identifies radiation exposure as an important consideration. Because Tauklarify is a radiopharmaceutical, administration contributes to a person's cumulative radiation exposure. The prescribing information recommends appropriate handling procedures and advises patients to hydrate before and after administration and to urinate frequently following the procedure.
The source reports no contraindications for Tauklarify.
There are also specific considerations involving medication use and breastfeeding. The supplied information states that CYP1A2 inducers, including tobacco smoking, should be avoided for at least seven days before Tauklarify administration. For individuals who are breastfeeding, temporary discontinuation is recommended, with pumping and discarding breast milk for a minimum of four hours after administration.
Important Limitations
Although Tauklarify provides another tool for Alzheimer’s evaluation, it has important limitations.
The safety and effectiveness of Tauklarify have not been established for evaluating non-Alzheimer’s disease tauopathies. In addition, performance may be lower in patients who are at earlier points on the pathological spectrum.
The source specifically warns that a negative Tauklarify scan does not necessarily rule out tau neurofibrillary tangle pathology. Similarly, a positive scan does not necessarily confirm the presence of the pathology. When clinical uncertainty remains, additional evaluation may be necessary.
These limitations highlight why imaging findings should be considered alongside other clinical and diagnostic information rather than interpreted in isolation.
What the Approval Could Mean for Alzheimer’s Care
The approval of Tauklarify adds another FDA-approved option to the field of Alzheimer’s disease assessment. As researchers and clinicians continue to focus on biological markers of the disease, tau imaging may become increasingly relevant to diagnostic evaluation and research.
Lantheus has indicated that it plans to continue supporting Alzheimer’s disease therapeutic programs through its Pharma Solutions business while evaluating the appropriate route toward broader commercial availability.
The broader significance of the approval will depend on how Tauklarify is incorporated into clinical practice, its availability, reimbursement and coverage, competition from other imaging approaches, and how tau imaging fits into evolving Alzheimer’s treatment strategies.
For patients and families, the most important point is that Tauklarify is an imaging agent, not an Alzheimer’s treatment. Its role is to provide information about tau pathology during an evaluation for the disease.
Final Thoughts
The FDA approval of Tauklarify marks a notable development in Alzheimer’s disease imaging. By providing a PET-based method for identifying tau neurofibrillary tangle pathology, the agent may offer clinicians additional biological information when assessing adults with cognitive impairment.
At the same time, the technology has defined limitations and should not be viewed as a definitive standalone diagnostic test. Its results need to be interpreted alongside clinical findings and other relevant assessments.
As Alzheimer’s research continues to evolve, tools capable of examining specific disease-related changes in the brain may contribute to a more detailed understanding of the condition and potentially support future advances in diagnosis and treatment development.
Sources
- Lantheus Holdings, Inc., announcement regarding FDA approval of Tauklarify, August 14, 2026.
- Tauklarify clinical study and safety information provided in the supplied source.
- Tauklarify indication, limitations, warnings, and safety information.
- Alzheimer’s Association, 2026 Alzheimer’s Disease Facts and Figures, cited in the supplied source.
Disclaimer
This article is provided for general informational and educational purposes only. It is not medical advice and should not be used to diagnose, treat, or prevent any medical condition. The information is based primarily on the supplied source material and may not include all information contained in the official prescribing information or regulatory documentation. Patients should discuss Alzheimer’s disease evaluation, PET imaging, Tauklarify, potential risks, and other diagnostic options with a qualified healthcare professional.